secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001193125-24-053575
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q4 net loss $13.8M ($0.06/shr); cash $611.2M; pipeline advances for NUV-868 and NUV-1511
--------------------------------------------------------------------------------

- Q4 net loss $13.8M ($0.06/shr); full-year net loss $75.8M, improved from $104.2M in 2022.
- Cash, equivalents and marketable securities $611.2M at Dec 31, 2023.
- Completed NUV-868 Phase 1 monotherapy, determined MTD; Phase 1b combo studies (olaparib/enzalutamide) ongoing.
- FDA cleared IND for NUV-1511, first DDC candidate; Phase 1/2 study expected to start H1 2024.
- Appointed Dr. Robert Mashal to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524053575/0001193125-24-053575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524053575/d786844d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-053575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer